FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
FDA approves Priovant's Lisraya as the first targeted therapy for dermatomyositis. The company plans to commercialize the treatment through specialty pharmacies in the United States.
Outcome Details
FDA approval for dermatomyositis, first targeted therapy in indication
Importance:8/10
Sentiment:
0.90
FDA approvalrare diseaseautoimmunefirst-in-indicationdermatology
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 28, 2026 10:42 AM